Abstract:
Objective:To study the relationship of LPPCN with neovascularization and to analyze its clini -copathologic significance, in an effort to find a new target for anti vascular therapies. Methods:Sixty-eight ma-lignant melanoma specimens were analyzed to observe the distribution of LPPCN and to examine the expression of CD 105 and TGF β 1 using immunohistochemistry. The distribution of vasculogenic mimicry (VM) was observed by immunohistochemical and histochemical double staining of CD31and PAS. Results: (1) The tu -mor cells undergoing LPPCN were darkly stained in the H&E-stained sections and distributed in patterns of lines and networks. Of the 68cases of melanoma,55.89% (38/68) were recognized as having LPPCN. (2) In malignant melanoma specimens, the rate of vasculogenic mimicry density (VMD) and microvessel density (MVD) labeled by CD 105 in LPPCN-positive group were higher than those in LPPCN-negative group, with sig-nificant differences (P<0.05). VMD and MVD were positively correlated with the density of LPPCN. The positive expression of TGF β 1 in LPPCN-positive group was higher than that in LPPCN-negative group and its ex -pression in the regions of LPPCN was obviously higher than that in circumambient tumor cells, with a signifi-cant difference (P<0.05). The expression of TGF β 1 was positively correlated with MVD labeled by CD105 . ( 3)There was no relationship between LPPCN and gender, age, site, tumor embolus, lymph node metastasis or distant metastasis ( P>0.05), but LPPCN was correlated with tumor size, mitosis figure count and Breslow depth (P<0.05). Kaplan-Meier survival analysis showed the survival rate of patients with LPPCN was lower than that of patients without LPPCN, with a statistical significance (P<0.05). The presence of LPPCN indicat-ed poor prognosis. Conclusion:LPPCN exists in malignant melanoma and is associated with VM and angio-genesis. Some tumor cells undergoing LPPCN have a spacial foundation for VM and angiogenesis. LPPCN can be an index for the evaluation of the prognosis of melanoma patients.